Document Detail


Alpha-1 adrenoceptor blockade with doxazosin in hypertension: effects on blood pressure and lipoproteins.
MedLine Citation:
PMID:  2565917     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The effects of doxazosin, a long-acting alpha-1 adrenoreceptor blocking drug, were observed upon blood pressure and serum lipoproteins. Thirty patients with supine diastolic blood pressure between 90 and 114 mm Hg during single-blind placebo therapy were randomized to double-blind treatment with either doxazosin or further placebo in a parallel-design protocol. Starting at one mg, dosage was doubled every 2 weeks during a 10-week treatment period to a maximum dose of 16 mg once daily. Blood was sampled in the fasting state before and during double-blind therapy for measurement of total cholesterol and triglycerides, cholesterol in the lipoprotein fractions, and apolipoproteins A and B. At the end of 10 weeks of titration, systolic and diastolic blood pressure were each reduced by 14 mm Hg in the standing position when measured 24 hours following the previous dose. Supine pressure was lowered by 6 mm Hg systolic and by 5 mm Hg diastolic at the same time point. Measured hourly for 12 hours following the ingestion of doxazosin, blood pressure was lowered maximally at 4-5 hours when an additional decline of 14/6 mm Hg (systolic/diastolic) was observed in the standing position and 13/6 in the supine posture. Postural dizziness, the most frequent symptomatic complaint, was reported in 4 patients during doxazosin treatment. After brief interruption of treatment in one and dosage adjustment in another, titration was continued in all four and no patient was withdrawn because of side effects. Concerning lipoproteins, the ratio of total cholesterol to HDL cholesterol and of LDL to HDL cholesterol both improved during treatment with doxazosin.(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
R P Ames; J Y Kiyasu
Related Documents :
9154957 - Effects of fosinopril on the blood pressure and lipid profile of patients undergoing he...
18800457 - Angiotensin ii antagonism improves the lipoprotein profile in patients with nephrotic s...
16813737 - Modifications of coronary risk factors.
21242097 - Analysis of signal propagation in an elastic-tube flow model.
8796387 - Relief of hypoxemia contributes to a reduction in cardiac index related to the use of p...
22966567 - Pattern uniformity in large-area ultraviolet nano-imprinting by a cylindrically inflate...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of clinical pharmacology     Volume:  29     ISSN:  0091-2700     ISO Abbreviation:  J Clin Pharmacol     Publication Date:  1989 Feb 
Date Detail:
Created Date:  1989-06-15     Completed Date:  1989-06-15     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0366372     Medline TA:  J Clin Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  123-7     Citation Subset:  IM    
Affiliation:
St. Luke's-Roosevelt Hospital, New York, NY 10019.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic alpha-Antagonists / therapeutic use*
Adult
Blood Pressure / drug effects
Clinical Trials as Topic
Double-Blind Method
Doxazosin
Female
Heart Rate / drug effects
Humans
Hypertension / blood,  drug therapy*,  physiopathology
Lipids / blood
Lipoproteins / blood*
Male
Prazosin / adverse effects,  analogs & derivatives*,  therapeutic use
Random Allocation
Chemical
Reg. No./Substance:
0/Adrenergic alpha-Antagonists; 0/Lipids; 0/Lipoproteins; 19216-56-9/Prazosin; 74191-85-8/Doxazosin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Immunoreactive somatostatin in male reproductive system in humans.
Next Document:  Bronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparis...